This disclosure relates to assays for detecting activating antibodies in a sample that are capable of antibody-dependent cell-mediated cytotoxicity. In certain embodiments, this disclosure relates to target cells comprising an antigen on the exterior of the cells and a luciferase inside the cells. In certain embodiments, the antigen is an Ebola-virus glycoprotein. In certain embodiments, this disclosure relates to detecting changes in chemiluminescence of the luciferase as an indication of activating antibodies in a sample capable of cell lysis when mixed with effector cells.

This disclosure relates to assays for detecting activating antibodies in a sample that are capable of antibody-dependent cell-mediated cytotoxicity. In certain embodiments, this disclosure relates to target cells comprising an antigen on the exterior of the cells and a luciferase inside the cells. In certain embodiments, the antigen is an Ebola-virus glycoprotein. In certain embodiments, this disclosure relates to detecting changes in chemiluminescence of the luciferase as an indication of activating antibodies in a sample capable of cell lysis when mixed with effector cells.

The present invention provides a novel multi-functional peptide that effectively regulates the activity of immune cells while also exhibiting excellent antibacterial activity against various bacteria such as Gram-negative bacteria and Gram-positive bacteria.

The present invention provides a novel multi-functional peptide that effectively regulates the activity of immune cells while also exhibiting excellent antibacterial activity against various bacteria such as Gram-negative bacteria and Gram-positive bacteria.

According to some embodiments, a method of reducing a likelihood of a pathogen binding to cell structures of a host comprises at least partially blocking the pathogen from binding to cell structures of the host as a result of competitive inhibition by delivering a carrier to the host, and at least partially reducing the likelihood of the pathogen binding to target areas of cell structures of the host.

According to some embodiments, a method of reducing a likelihood of a pathogen binding to cell structures of a host comprises at least partially blocking the pathogen from binding to cell structures of the host as a result of competitive inhibition by delivering a carrier to the host, and at least partially reducing the likelihood of the pathogen binding to target areas of cell structures of the host.

The present invention provides compositions and methods for transducing cells (e.g. T cells or immune cells). Also provided herein are methods of treating a disease in a subject in need thereof.

The present invention provides compositions and methods for transducing cells (e.g. T cells or immune cells). Also provided herein are methods of treating a disease in a subject in need thereof.

The disclosure generally provides recombinant proteins comprising Tobamovirus capsid proteins and an immunogenic epitope of an antigen of interest. The recombinant protein can be used to assemble an array comprising a plurality of associated recombinant proteins that can enhance the immunogenicity of the epitope and induce and/or enhance an immune response to the antigen. The disclosure also provides compositions, such as vaccines, that include the recombinant protein as well as methods for inducing and/or enhancing an immune response in a mammal.

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).